Paper Details

  1. Home
  2. Paper Details

Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapy.

Author: BarrPaul M, BarrientosJacqueline C, BranderDanielle M, ChesonBruce D, DorseyColleen, FlinnIan W, FonsecaGustavo A, GhoshNilanjan, HamadehIssam S, KambhampatiSuman, LaRattaNicole, LamannaNicole, LansiganFrederick, Luning PrakEline T, MatoAnthony R, MiskinHari P, PagelJohn M, PaskalisDana, PuJeffrey J, RaiKanti R, ReevesJames A, RoekerLindsey, SchusterStephen J, SitlingerAndrea, SkarbnikAlan P, SportelliPeter, SvobodaJakub, TsaoPatricia, WeissMichael S, WeissbrotHanna

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This phase 2 trial (NCT02742090) evaluated the efficacy and safety of umbralisib in CLL patients who were intolerant to prior BTK inhibitor (BTKi) or PI3K inhibitor (PI3Ki) therapy. Median PFS was 23.5 months (95% CI, 13.1-not estimable), with 58% of patients on umbralisib for a longer duration than prior KI.
Paper Details　
Original Abstract of the Article :
Intolerance is the most common reason for kinase inhibitor (KI) discontinuation in chronic lymphocytic leukemia (CLL). Umbralisib, a novel highly selective phosphatidylinositol 3-kinase δ (PI3Kδ)/CK1ε inhibitor, is active and well tolerated in CLL patients. In this phase 2 trial (NCT02742090), umbra...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8574211/

データ提供：米国国立医学図書館（NLM）

Navigating the Shifting Sands of CLL Treatment: Umbralisib Offers a New Path

Chronic lymphocytic leukemia (CLL) is a type of blood cancer that can be challenging to treat. This study is like an intrepid explorer navigating the shifting sands of CLL treatment, searching for a new and effective path for patients who have not responded well to previous therapies. The study explores the efficacy and safety of umbralisib, a new PI3Kδ/CK1ε inhibitor, in patients who have developed intolerance to other kinase inhibitors.

A New Oasis in the Desert of Treatment Options

The study found that [umbralisib was active and well-tolerated in CLL patients who were intolerant to prior BTK inhibitor or PI3K inhibitor therapy]. This finding is like discovering a hidden oasis in the desert of CLL treatment, offering a new and potentially more effective option for patients who have exhausted other therapies.

Hope for CLL Patients

This research offers hope for patients with CLL who have experienced intolerance to previous therapies. The study suggests that [umbralisib may provide a viable treatment option that can induce durable responses and improve quality of life] for these patients.

Dr. Camel's Conclusion

This study, like a wise camel navigating the desert, provides valuable information for the treatment of CLL. The findings suggest that umbralisib may be a new and promising option, offering a haven of hope for patients who have struggled with other therapies.

Date :
  1. Date Completed 2021-12-07
  2. Date Revised 2023-04-13
Further Info :

Pubmed ID

33259589

DOI: Digital Object Identifier

PMC8574211

Related Literature

Article Analysis
・Effects of umbralisib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.